8-K: Tevogen Bio Receives Nasdaq Deficiency Notice

Tevogen Bio Holdings Inc. has been notified by Nasdaq that it fails to meet minimum market value requirements for continued listing.

Summary

• Tevogen Bio received notice from Nasdaq on April 16, 2026, regarding failure to meet the $50 million minimum market value of listed securities (MVLS) requirement.
• On April 17, 2026, the company received a second notice regarding failure to meet the $15 million minimum market value of publicly held shares (MVPHS) requirement.
• The company has 180 calendar days, until October 13 and October 14, 2026, respectively, to regain compliance.
• The notifications have no immediate impact on the company's current listing or trading status on the Nasdaq Global Market.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative development, as it highlights significant market valuation pressure and potential delisting risk, which typically weighs heavily on investor confidence.

Positives

• The company has been granted a 180-day grace period to regain compliance with Nasdaq listing standards.
• There is no immediate effect on the company's ability to trade on the Nasdaq Global Market.

Negatives

• Failure to meet the $50 million minimum market value of listed securities requirement.
• Failure to meet the $15 million minimum market value of publicly held shares requirement.
• Increased risk of potential delisting if compliance is not regained within the allotted timeframe.

Risks

• Potential delisting from the Nasdaq Global Market if compliance is not met by October 2026.
• The company may be forced to transfer to the Nasdaq Capital Market if it cannot meet Global Market standards.
• No assurance that the company will be able to regain compliance with Nasdaq listing rules.

Future Outlook

The company intends to monitor its market value and evaluate options to regain compliance, including potentially applying for a transfer to the Nasdaq Capital Market, though success is not guaranteed.

Management Comments

• The company intends to actively monitor the market value of its listed securities and publicly held shares.
• The company may evaluate and consider available options for regaining compliance with the Requirements, as well as applying for a transfer to The Nasdaq Capital Market.

Industry Context

StockSavvy.ai notes that receiving deficiency notices for market value is a common challenge for small-cap biotech firms facing market volatility, often necessitating strategic pivots or capital restructuring to maintain exchange eligibility.

Comparison to Industry Standards

• Nasdaq Global Market listing standards are among the most stringent in the industry.
• Many small-cap biotech companies frequently utilize the 180-day grace period to restore market valuation through operational milestones or corporate actions.

Stakeholder Impact

• Shareholders face increased uncertainty regarding the company's listing status.
• Potential for increased stock price volatility as the compliance deadlines approach.

Next Steps

• Monitor market value of listed securities and publicly held shares.
• Evaluate options to regain compliance with Nasdaq requirements.
• Consider application for transfer to the Nasdaq Capital Market.

Key Dates

Recommendation

The receipt of a deficiency notice regarding market value indicates significant underlying financial or market-sentiment weakness, suggesting a high risk of further downside or potential delisting, which warrants a cautious 'sell' or 'avoid' stance until compliance is restored.

Keywords

Tevogen Bio, Nasdaq, Delisting, Compliance, TVGN, Market Value, SEC Filing